Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 124

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 124
---
, and 2023, respectively;              
 ───────────────────────────────────────────────────────────────────────────────────────

  Net operating cash outflows of approximately $19,700 thousand and $21,577 thousand in 2024 and 2023,  
  respectively; and                                                                                     
  Net operating cash outflows of approximately $19,700 thousand and $21,577 thousand in 2024 and 2023,  
  respectively; and                                                                                     
 ────────────────────────────────────────────────────────────────────────────────────────────────────────

  Our accumulated deficit balance as of December 31, 2024, is approximately $274,071 thousand.  

We have approved a plan to improve our available cash balances,
liquidity and cash flows generated from operations. We have identified several potential actions including cost preservation measures
that would be initiated in a timely manner to address our liquidity needs over the twelve-month period from the date of this Annual Report,
as follows:

  Reducing non-essential expenses and implement headcount reductions to conserve cash  

  Deferral and reprioritization of certain research and development programs that would  

We have a history of operating losses and negative cash flows
from operations. However, despite these conditions, we believe that the management’s plans, as described more fully above, will
provide sufficient liquidity to meet our financial obligations and maintain levels of liquidity over the twelve-month period from the
date of this Annual Report. Therefore, management concluded this plan alleviate the substantial doubt that was raised about our ability
to continue as a going concern for at least twelve months from the date of this Annual Report.

Revenue Recognition

We recognize revenues when the control over the goods or services
is transferred to the customer. The transaction price is the amount of consideration that is expected to be received based on the contract
terms, excluding amounts collected on behalf of third parties (such as taxes). We don’t grant a right of return to our customers.

If the contract contains a single performance obligation, the entire transaction price
is allocated to the single performance obligation. Contracts that contain multiple performance obligations such as licenses, services,
royalties and milestone events require an allocation of the transaction price to each performance obligation based on a relative standalone
selling price, or SSP. To determine SSP, we maximize the use of observable standalone sales and observable data, where available. In instances
where performance obligations do not have observable standalone sales, we utilize available information that may include market conditions,
pricing strategies, the economic life of the software, and